title: Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
abstract: BACKGROUND
  A meta and pooled analysis of published and unpublished case-control studies was performed to evaluate the association of CYP17 (rs743572) and CYP3A4 (rs2740574) polymorphisms and prostate cancer (PCa) in men from the USA, Caribbean, and Africa.
  
  
  METHODS
  Eight publications (seven studies) and two unpublished studies for CYP17 included 1,580 subjects (559 cases and 1,021 controls) and eleven publications and three unpublished studies for CYP3A4 included 3,400 subjects (1,429 cases and 1,971 controls).
  
  
  RESULTS
  Overall, the CYP17 heterozygous and homozygous variants were not associated with PCa, but they confer a 60% increased risk of PCa in a sub-group analysis restricted to African-American men (T/C + C/C, OR: 1.6, 95% CI: 1.1-2.4). No associations were observed for CYP3A4, overall and in stratified analyses for African-Americans and Africans. The pooled analysis suggests that after adjusting for study, age, PSA, and family history of PCa, CYP17 was associated with PCa for men of African ancestry (Adjusted OR: 3.5, 95% CI: 1.2-10.0).
  
  
  CONCLUSIONS
  Our findings suggest that genetic factors involved in the androgen pathway play a role in PCa risk among men of African ancestry.
authors.affiliation: North Shore Long Island Jewish Health System, The Feinstein Institute for Medical Research, Manhasset, New York 11030, USA. taiolema@gmail.com
authors.forename: Emanuela
authors.initials: E
authors.lastname: Taioli
authors.forename: Vestra
authors.initials: V
authors.lastname: Sears
authors.forename: Alexis
authors.initials: A
authors.lastname: Watson
authors.forename: Rafael E
authors.initials: RE
authors.lastname: Flores-Obando
authors.forename: Maria D
authors.initials: MD
authors.lastname: Jackson
authors.forename: Flora A
authors.initials: FA
authors.lastname: Ukoli
authors.forename: Ilce M
authors.initials: IM
authors.lastname: de Syllos Cólus
authors.forename: Pedro
authors.initials: P
authors.lastname: Fernandez
authors.forename: Norma
authors.initials: N
authors.lastname: McFarlane-Anderson
authors.forename: Elaine A
authors.initials: EA
authors.lastname: Ostrander
authors.forename: Iara S
authors.initials: IS
authors.lastname: Rodrigues
authors.forename: Janet L
authors.initials: JL
authors.lastname: Stanford
authors.forename: Jack A
authors.initials: JA
authors.lastname: Taylor
authors.forename: Marshall
authors.initials: M
authors.lastname: Tulloch-Reid
authors.forename: Camille C R
authors.initials: CC
authors.lastname: Ragin
mesh_terms: D000328:Adult; D001741:Black or African American / Q000235:genetics* / Q000706:statistics & numerical data*; D000368:Aged; D017691:Caribbean Region / Q000453:epidemiology; D016022:Case-Control Studies; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000208:ethnology / Q000235:genetics; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D011110:Polymorphism, Genetic / Q000235:genetics; D011471:Prostatic Neoplasms / Q000208:ethnology* / Q000235:genetics*; D012307:Risk Factors; D018426:SEER Program / Q000706:statistics & numerical data; D013254:Steroid 17-alpha-Hydroxylase / Q000235:genetics*; D014481:United States / Q000453:epidemiology
chemical_list: D051544:Cytochrome P-450 CYP3A; C501892:CYP17A1 protein, human; D013254:Steroid 17-alpha-Hydroxylase; C510163:CYP3A4 protein, human